Biocon Ltd. has achieved a significant breakthrough as the Medicines and Healthcare Products Regulatory Agency (MHRA) U.K. granted approval for its Liraglutide formulation, facilitated through its European partner, Zentiva. This complex 6 mg/ml solution for injection in pre-filled pens targets type 2 Diabetes Mellitus, a condition characterized by insulin deficiency or resistance. Siddharth Mittal, Biocon's MD & CEO, hailed this as a pivotal milestone, stressing the swift commercialization plans in collaboration with Zentiva.